Leonardo Kapural, MD discusses interim results from SENZA-CAP in a SmartTRAK interview at ASRA 2017

At the recent American Society of Regional Anesthesia and Pain Medicine (ASRA)
annual meeting in Lake Buena Vista, FL, Leonardo Kapural, MD, professor of anesthesiology at Wake Forest University and principle investigator of the SENZA-RCT, presented interim three month results from SENZA-CAP, a multicenter feasibility study evaluating use of 10 kHz spinal cord stimulation (SCS) for the treatment of chronic abdominal pain (CAP). (See ASRA Poster 4491.)

In an interview at ASRA, SmartTRAK spoke to Dr. Kapural regarding key findings from this study, the addressable market for SCS in chronic abdominal pain, patient engagement as a potential variable, and what’s next for this research.

A transcript of SmartTRAK’s interview with Dr. Kapural is below. Or click on the following video to view the interview recorded live at ASRA 2017. (12:06 minutes.)

Closed-Loop Spinal Cord Stim: The Next Big Thing?

With impressive preliminary data from Saluda Medical’s AVALON trial, and all the big players working on evoked potentials, will closed-loop spinal cord stimulation (#SCS) be the next big thing?

Society of NeuroInterventional Surgery (SNIS) President Donald F. Frei, MD talked with SmartTRAK at the SNIS 14^th Annual Meeting regarding the future of neurointerventional surgery. 

Don Frei, MD, President of the Society of NeuroInterventional Surgery (SNIS), discusses key studies, trends, and technologies affecting the market for mechanical thrombectomy devices in an interview with SmartTRAK at the SNIS 14th Annual Meeting July 24-27, 2017 in Colorado Springs, CO.

A transcript of SmartTRAK’s interview with Don Frei, MD, is below. To listen to the audio interview recorded live at SNIS 2017, click here . 

SmartTRAK reports on two studies presented at INS 2017 evaluating the effect of VNS paired with rehab in stroke patients with upper limb paralysis.

One of the hottest emerging applications for neuromodulation is for improving function and movement in patients paralyzed by a stroke. Stroke affects almost 800,000 people every year in the US alone and is a leading cause of long-term disability, with an annual cost to the healthcare system of ~$33 billion.

At the International Neuromodulation Society (INS) 13th Annual Congress May 26-June 3 in Edinburgh, SmartTRAK interviewed Jesse Dawson, MD, Clinical Lead, Scottish Stroke Research Network, and Teresa Kimberley, PT, PhD Associate Professor, Division of Physical Therapy at the University of Minnesota, regarding a randomized, double-blinded trial evaluating the effect of vagal nerve stimulation (VNS) during stroke rehabilitation on upper limb function after an ischemic stroke using Microtransponder’s Vivistim System...

International Neuromodulation Society (INS) President Tim Deer, MD discusses important research results as well as key trends and technologies in neuromodulation.

Timothy Deer, MD, FIPP, President of the International Neuromodulation Society (INS),  at the INS 13th Annual Congress May 26-June 3 highlighted key studies, trends and technologies in neuromodulation in an interview with SmartTRAK in Edinburgh, Scotland...

Nevro:  The One to Beat!

In an interview with BioMedGPS, Nevro CEO Rami Elghandour discussed the Company’s success, its growth strategies, and some of the challenges of being the one to beat in the spinal cord stimulation (SCS) market.

Since disrupting the market with its paresthesia-free high frequency (HF10) Senza SCS System, Nevro has set a new standard of care for SCS with unparalleled clinical evidence and success in treating chronic intractable leg and back pain.

And Anne Staylor is off and running!

Meet with Anne Staylor at #INS2017, Senior SmartTRAK Analyst and Managing Editor, and get your questions answered about SmartTRAK and Neuro Therapies business, market and competitive intelligence. 

 SmartTRAK will be at the International Neuromodulation Society 13th World Congress “Neuromodulation: Technology Changing Lives” in Edinburgh, Scotland May 27- June 1. Meet with Anne Staylor, Senior SmartTRAK Analyst and Managing Editor!

It’s been less than a year since Nuvectra Medical spun-off from Greatbatch Inc. (now Integer), and in that time Nuvectra has built a sales organization and laid the organizational foundation to become a, multi-indication neurostimulation company.

In an interview with BioMedGPS, Medtronic’s Marshall Stanton, MD discussed the Company’s strategies for gaining back market share in spinal cord stimulation and ongoing efforts to find the sweet spot in treating chronic intractable pain.